166 related articles for article (PubMed ID: 23054215)
1. The spectrum of urological malignancy in Lynch syndrome.
Barrow PJ; Ingham S; O'Hara C; Green K; McIntyre I; Lalloo F; Hill J; Evans DG
Fam Cancer; 2013 Mar; 12(1):57-63. PubMed ID: 23054215
[TBL] [Abstract][Full Text] [Related]
2. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
[TBL] [Abstract][Full Text] [Related]
3. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.
Win AK; Lindor NM; Winship I; Tucker KM; Buchanan DD; Young JP; Rosty C; Leggett B; Giles GG; Goldblatt J; Macrae FA; Parry S; Kalady MF; Baron JA; Ahnen DJ; Marchand LL; Gallinger S; Haile RW; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2013 Feb; 105(4):274-9. PubMed ID: 23385444
[TBL] [Abstract][Full Text] [Related]
4. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
[TBL] [Abstract][Full Text] [Related]
5. Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome.
Wischhusen JW; Ukaegbu C; Dhingra TG; Uno H; Kastrinos F; Syngal S; Yurgelun MB
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):193-199. PubMed ID: 31615790
[TBL] [Abstract][Full Text] [Related]
6. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
7. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.
Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT
Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828
[TBL] [Abstract][Full Text] [Related]
8. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies.
Ryan NAJ; Morris J; Green K; Lalloo F; Woodward ER; Hill J; Crosbie EJ; Evans DG
JAMA Oncol; 2017 Dec; 3(12):1702-1706. PubMed ID: 28772289
[TBL] [Abstract][Full Text] [Related]
9. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC).
Geary J; Sasieni P; Houlston R; Izatt L; Eeles R; Payne SJ; Fisher S; Hodgson SV
Fam Cancer; 2008; 7(2):163-72. PubMed ID: 17939062
[TBL] [Abstract][Full Text] [Related]
10. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
[TBL] [Abstract][Full Text] [Related]
11. Risks of less common cancers in proven mutation carriers with lynch syndrome.
Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
[TBL] [Abstract][Full Text] [Related]
12. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.
Barrow E; Robinson L; Alduaij W; Shenton A; Clancy T; Lalloo F; Hill J; Evans DG
Clin Genet; 2009 Feb; 75(2):141-9. PubMed ID: 19215248
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
14. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.
Guindalini RS; Win AK; Gulden C; Lindor NM; Newcomb PA; Haile RW; Raymond V; Stoffel E; Hall M; Llor X; Ukaegbu CI; Solomon I; Weitzel J; Kalady M; Blanco A; Terdiman J; Shuttlesworth GA; Lynch PM; Hampel H; Lynch HT; Jenkins MA; Olopade OI; Kupfer SS
Gastroenterology; 2015 Nov; 149(6):1446-53. PubMed ID: 26248088
[TBL] [Abstract][Full Text] [Related]
15. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study.
International Mismatch Repair Consortium
Lancet Oncol; 2021 Jul; 22(7):1014-1022. PubMed ID: 34111421
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
17. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer.
Lin KM; Shashidharan M; Thorson AG; Ternent CA; Blatchford GJ; Christensen MA; Watson P; Lemon SJ; Franklin B; Karr B; Lynch J; Lynch HT
J Gastrointest Surg; 1998; 2(1):67-71. PubMed ID: 9841970
[TBL] [Abstract][Full Text] [Related]
18. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.
Dominguez-Valentin M; Sampson JR; Seppälä TT; Ten Broeke SW; Plazzer JP; Nakken S; Engel C; Aretz S; Jenkins MA; Sunde L; Bernstein I; Capella G; Balaguer F; Thomas H; Evans DG; Burn J; Greenblatt M; Hovig E; de Vos Tot Nederveen Cappel WH; Sijmons RH; Bertario L; Tibiletti MG; Cavestro GM; Lindblom A; Della Valle A; Lopez-Köstner F; Gluck N; Katz LH; Heinimann K; Vaccaro CA; Büttner R; Görgens H; Holinski-Feder E; Morak M; Holzapfel S; Hüneburg R; Knebel Doeberitz MV; Loeffler M; Rahner N; Schackert HK; Steinke-Lange V; Schmiegel W; Vangala D; Pylvänäinen K; Renkonen-Sinisalo L; Hopper JL; Win AK; Haile RW; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Wadt K; Therkildsen C; Okkels H; Ketabi Z; Moreira L; Sánchez A; Serra-Burriel M; Pineda M; Navarro M; Blanco I; Green K; Lalloo F; Crosbie EJ; Hill J; Denton OG; Frayling IM; Rødland EA; Vasen H; Mints M; Neffa F; Esperon P; Alvarez K; Kariv R; Rosner G; Pinero TA; Gonzalez ML; Kalfayan P; Tjandra D; Winship IM; Macrae F; Möslein G; Mecklin JP; Nielsen M; Møller P
Genet Med; 2020 Jan; 22(1):15-25. PubMed ID: 31337882
[TBL] [Abstract][Full Text] [Related]
19. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry.
Pande M; Wei C; Chen J; Amos CI; Lynch PM; Lu KH; Lucio LA; Boyd-Rogers SG; Bannon SA; Mork ME; Frazier ML
Fam Cancer; 2012 Sep; 11(3):441-7. PubMed ID: 22714864
[TBL] [Abstract][Full Text] [Related]
20. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT
J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
